Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.

about

Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.

Item

http://www.wikidata.org/entity/Q52673089

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Real-world outcomes in patient ...... ancer treated with crizotinib.

@en

Real-world outcomes in patient ...... ancer treated with crizotinib.

@nl

type

Item

label

Real-world outcomes in patient ...... ancer treated with crizotinib.

@en

Real-world outcomes in patient ...... ancer treated with crizotinib.

@nl

prefLabel

Real-world outcomes in patient ...... ancer treated with crizotinib.

@en

Real-world outcomes in patient ...... ancer treated with crizotinib.

@nl

P1476

Real-world outcomes in patient ...... ancer treated with crizotinib.

@en

P2093

E T Masters

http://www.w3.org/2001/XMLSchema#string

J A Kaye

http://www.w3.org/2001/XMLSchema#string

K L Davis

http://www.w3.org/2001/XMLSchema#string

S Iyer

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

New driver mutations in non-small-cell lung cancer.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

P304

e40-e49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.3723

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29507494

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib

P932

5832290

http://www.w3.org/2001/XMLSchema#string